Candel Therapeutics updates Phase 3 CAN-2409 data in localized prostate cancer trial

Candel Therapeutics, Inc.

Candel Therapeutics, Inc.

CADL

0.00
  • Candel Therapeutics scheduled investor webcast for May 15, 2026, to discuss extended follow-up from its phase 3 trial of aglatimagene besadenovec (CAN-2409) in intermediate- to high-risk localized prostate cancer.
  • Results will be presented in a future oral plenary session at American Urological Association 2026 Annual Meeting, with call set to follow that presentation.
  • Update centers on longer-term patient outcomes from the late-stage study, a key readout for assessing whether CAN-2409 can support a regulatory path in localized prostate cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605040805PRIMZONEFULLFEED9712155) on May 04, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.